Oncyte is focused on a portfolio of immuno-oncology CAR T cell therapies for cancer. Unlike traditional Chimeric Antigen Receptor (CAR) technologies, Oncyte’s therapies use the human Natural Killer cell receptor, NKG2D, to target stress ligands expressed on a wide range of cancers. In addition, Oncyte is also developing a non-gene edited allogeneic T cell receptor (TCR) Inhibitory Molecule (TIM) technology.